NYSE:HIMS
Hims & Hers Health, Inc.
A leading digital-first telehealth provider expanding its direct-to-consumer portfolio of men's and women's health products via proprietary technology platforms.
Key Metrics
Investment Thesis
Bull Case
Explosive revenue growth and consistent profitability demonstrate a scalable business model with strong unit economics in the booming digital health sector. The company's diversified product portfolio reduces reliance on single categories while expanding total addressable market for both male and female wellness solutions. Strong balance sheet with $228.6M cash provides ample flexibility for strategic acquisitions or R&D investments to further accelerate growth.
Bear Case
Valuation multiples may be stretched given the high-growth expectations required to justify current share price levels in a volatile market environment. Heavy investment in customer acquisition could persistently pressure margins if conversion rates plateau despite technological advancements. Regulatory uncertainty surrounding digital prescriptions and telehealth services poses an ongoing threat to revenue stability and long-term projections.
About Hims & Hers Health, Inc.
Hims & Hers Health, Inc. is a digital-first telehealth platform serving men and women across North America with direct-to-consumer health products and services. The company leverages proprietary technology to deliver personalized care for conditions like hair loss, erectile dysfunction, and mental wellness through its HIMS and HERS brands. Financial performance reflects strong top-line growth driven by expanded product offerings and increasing customer adoption of digital health solutions.
Analysis
Management Discussion
The company achieved significant financial turnaround, transitioning from net losses in 2022-2023 to sustained profitability with $128.4M net income in the latest period. Revenue surged 60% year-over-year to $2.35B, demonstrating successful execution of product diversification and market expansion strategies. Operating cash flow strengthened considerably at $300.0M, supported by disciplined working capital management and positive adjustments from non-cash items.
Industry Overview
The digital health industry is experiencing rapid expansion as consumers increasingly prefer convenient, technology-enabled healthcare solutions for common conditions. Telehealth platforms are gaining traction by integrating prescription services with direct-to-consumer retail models, disrupting traditional clinic-based care delivery. Market consolidation is likely as successful players acquire smaller competitors to expand product offerings and geographic reach.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $526.9M | $872.0M | $1.48B | $2.35B |
| Cost of Revenue | $118.2M | $157.1M | $303.4M | $614.3M |
| Gross Profit | $408.7M | $714.9M | $1.17B | $1.73B |
| Operating Expenses | $477.4M | $744.4M | $1.11B | $1.63B |
| Operating Income | $-68.7M | $-29.5M | $61.9M | $105.6M |
| G&A | $98.2M | $129.9M | $167.8M | $272.7M |
| Stock-Based Comp | $42.8M | $66.1M | $92.3M | $135.2M |
| D&A | $7.5M | $9.5M | $17.1M | $54.5M |
| Amortization | $4.1M | $3.5M | $3.8M | $23.7M |
| Other OpEx | $379.2M | $614.5M | $943.5M | $1.36B |
| Non-Operating Income | $3.0M | $7.9M | $9.8M | $18.3M |
| Pre-Tax Income | $-65.7M | $-21.6M | $71.7M | $123.9M |
| Income Tax | $-31.0K | $2.0M | $-54.3M | $-4.4M |
| Continuing Ops | $-65.7M | $-23.5M | $126.0M | $128.4M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-65.7M | $-23.5M | $126.0M | $128.4M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-65.7M | $-23.5M | $126.0M | $128.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $216.6M | $265.1M | $395.8M | $767.6M |
| Cash & Equivalents | $46.8M | $96.7M | $220.6M | $228.6M |
| Accounts Receivable | $3.9M | $6.7M | $6.1M | $32.1M |
| Inventory | $21.6M | $22.5M | $64.4M | $80.1M |
| Prepaid Expenses | $15.4M | $21.6M | $31.2M | $110.0M |
| Other Current Assets | $129.0M | $117.6M | $73.6M | $316.8M |
| Long-Term Assets | $149.7M | $176.1M | $311.7M | $1.39B |
| PP&E (Net) | $3.0M | — | — | — |
| Intangibles | $21.8M | $18.6M | $43.4M | $196.1M |
| Goodwill | $110.9M | $110.9M | $112.7M | $278.3M |
| Operating Leases | $4.9M | $9.6M | $10.9M | $137.0M |
| Other LT Assets | $9.1M | $37.1M | $144.7M | $775.6M |
| Total Assets | $366.3M | $441.2M | $707.5M | $2.15B |
| Current Liabilities | $47.9M | $88.5M | $221.4M | $404.4M |
| Accounts Payable | $32.4M | $43.1M | $91.2M | $143.3M |
| Current Leases | $1.7M | $1.3M | $1.9M | $4.8M |
| Deferred Revenue | $1.5M | $7.7M | $75.3M | $127.2M |
| Other Current Liab | $0 | $7.4M | $0 | $50.6M |
| Long-Term Liabilities | $6.7M | $8.7M | $9.5M | $1.21B |
| LT Operating Leases | $3.6M | $8.7M | $9.5M | $143.2M |
| Other LT Liab | $3.0M | $22.0K | $0 | $1.07B |
| Total Liabilities | $54.6M | $97.2M | $230.8M | $1.61B |
| Shareholders' Equity | $311.7M | $344.0M | $476.7M | $540.9M |
| Retained Earnings | $-344.6M | $-368.2M | $-242.1M | $-113.8M |
| AOCI | $-277.0K | $-124.0K | $-324.0K | $2.3M |
| Total L&E | $366.3M | $441.2M | $707.5M | $2.15B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-65.7M | $-23.5M | $126.0M | $128.4M |
| Non-Cash Adjustments | $14.5M | $61.5M | $-58.7M | $68.6M |
| Working Capital Changes | $24.6M | $35.5M | $183.8M | $103.0M |
| Cash from Operations | $-26.5M | $73.5M | $251.1M | $300.0M |
| Cash from Investing | $34.7M | $-12.1M | $-19.0M | $-1.02B |
| Debt Repayments | $0 | — | — | — |
| Share Buybacks | $0 | $2.0M | $83.0M | $90.0M |
| Cash from Financing | $-33.1M | $-11.5M | $-107.8M | $729.6M |
| FX Effect | $-53.0K | $-11.0K | $-270.0K | $2.5M |
| Net Change in Cash | $-25.0M | $49.9M | $123.9M | $7.2M |
| Beginning Cash | $72.6M | $47.6M | $97.5M | $221.4M |
| Ending Cash | $47.6M | $97.5M | $221.4M | $228.6M |
Frequently Asked Questions
How does Hims & Hers Health, Inc. make money?
Primary revenue streams include branded consumer health products (telemedicine consultations, prescription fulfillment, and retail merchandise) for male and female wellness categories. Additional segments encompass marketplace sales where third-party brands are listed alongside Hims & Hers proprietary lines. The company also generates revenue through specialized services such as dermatology, endocrinology, and mental health counseling integrated into its digital ecosystem.
What are the main risks for HIMS?
Regulatory changes regarding telehealth reimbursement or digital prescription regulations could impact operational margins and scalability. Intense competition from established pharmaceutical companies and new digital health entrants may erode market share and pricing power. Dependence on third-party logistics partners for product fulfillment introduces supply chain vulnerabilities that could disrupt delivery timelines. High customer acquisition costs in a crowded digital health space could compress profitability if growth decelerates.
What is HIMS's competitive advantage?
Proprietary direct-to-consumer technology platforms enable seamless integration of telehealth consultations with at-home product fulfillment, creating a highly convenient user experience. Strong brand recognition in men's and women's health categories allows for premium pricing and high customer retention rates. Data-driven personalization engines optimize treatment plans and marketing efficacy, driving efficient customer acquisition costs compared to traditional healthcare providers.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.